Advertisement
Advertisement
U.S. Markets close in 4 hrs 59 mins
Advertisement
Advertisement
Advertisement
Advertisement

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.5493-0.0138 (-2.45%)
As of 11:00AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5631
Open0.5400
Bid0.5441 x 1000
Ask0.5450 x 1100
Day's Range0.5400 - 0.5575
52 Week Range0.4100 - 4.6300
Volume251,980
Avg. Volume728,525
Market Cap68.937M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress

    Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven upcoming presentations at ASGCT highlight application of HSC approach including clinical and research programs Cash and investments of approximately $200M provide runway into 2024 BOSTON and LO

  • GlobeNewswire

    Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond

    BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19 in Washington, D.C. Featured presentations include updated results on the OTL-203 clinical program for mucopolysaccharidosis type I Hurler syndrome (MPS-IH), as well as several accepted abstracts highlighting

  • GlobeNewswire

    Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results

    BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review business updates and its first quarter 2022 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. The conference call can be accessed by dialing +1 (

Advertisement
Advertisement